Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Refined characterization of circulating tumor DNA through biological feature integration

View ORCID ProfileHavell Markus, View ORCID ProfileDineika Chandrananda, View ORCID ProfileElizabeth Moore, View ORCID ProfileFlorent Mouliere, James Morris, View ORCID ProfileJames Brenton, View ORCID ProfileChristopher G. Smith, View ORCID ProfileNitzan Rosenfeld
doi: https://doi.org/10.1101/2021.08.11.21261907
Havell Markus
1Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Havell Markus
Dineika Chandrananda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dineika Chandrananda
Elizabeth Moore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elizabeth Moore
Florent Mouliere
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Florent Mouliere
James Morris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Brenton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James Brenton
Christopher G. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher G. Smith
Nitzan Rosenfeld
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nitzan Rosenfeld
  • For correspondence: nitzan.rosenfeld@cruk.cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Circulating tumor DNA (ctDNA) in blood plasma is present at very low concentrations compared to cell-free DNA (cfDNA) of non-tumor origin. To enhance ctDNA detection, recent studies have been focused on understanding the non-random fragmentation pattern of cfDNA. These studies have investigated fragment sizes, genomic position of fragment end points, and fragment end motifs. Although these features have been described and shown to be aberrant in cancer patients, there is a lack of understanding of how the individual and integrated analysis of these features enrich ctDNA fraction and enhance ctDNA detection.

Using whole genome sequencing and copy number analysis of plasma samples from 5 high grade serious ovarian cancer patients, we observed that 1) ctDNA is enriched not only in fragments shorter than mono-nucleosomes (∼167bp), but also in those shorter than di-nucleosomes (∼240-330bp) (28-159% enrichment). 2) fragments that start and end at the border or within the nucleosome core are enriched in ctDNA (5-46% enrichment). 3) certain DNA motifs conserved in regions 10bp up- and down-stream of fragment ends (i.e. cleavage sites) could be used to detect tumor-derived fragments (10-44% enrichment). We further show that the integrated analysis of these three features resulted in a higher enrichment of ctDNA when compared to using fragment size alone (additional 7-25% enrichment after fragment size selection).

We believe these genome wide features, which are independent of genetic mutational changes, could allow new ways to analyze and interpret cfDNA data, as significant aberrations of these features from a healthy state could improve its utility as a diagnostic biomarker.

Significance In recent years circulating tumor DNA (ctDNA) has received much attention, and investment, as a biomarker that could transform the clinical care of cancer patients. Despite this, there is much that is not known about this biomarker. Recently, it has been demonstrated that the biological properties of ctDNA can be leveraged to improve ctDNA based assays. Here we build on this by carrying out an in-depth analysis of three genome wide fragmentation patterns of cell-free DNA; specifically fragment size, positioning of fragment end points with respect to nucleosome occupancy, and fragment end motifs. Whilst previous studies have described these features in an individual manner and used them as point statistics for comparison between healthy individuals and cancer patients, our study is the first to show that the individual and integrative analysis of these features can be used to enrich for ctDNA and enable enhanced ctDNA detection. The features described are independent of specific genomic alterations, with signal integrated across the breadth of the genome. This allows informative analysis that leverages a larger proportion of sequencing reads, further building the case for the use of cost-effective approaches like shallow whole genome sequencing for cancer diagnostics.

Competing Interest Statement

N.R. and J.B. are co-founders, present/former officers or consultants and/or shareholders of Inivata Ltd, a cancer genomics company that commercialises circulating DNA analysis. C.G.S. has consulted for Inivata Ltd. Inivata had no role in the conception, design, data collection and analysis of the study. Other co-authors have no conflict of interests.

Funding Statement

This study was supported by grants from CRUK Cambridge Institute (Core Grant, A29580) and by funding from the ERC under the European Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement n. 337905.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The plasma samples from cancer patients were collected at Addenbrooke Hospital, Cambridge, UK, approved by the local research ethics committee (REC reference number: 07/Q0106/63; and National Research Ethics Service Committee East of England Cambridge Central 03/018).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Centre Amsterdam, 1081 HV, Amsterdam, The Netherlands.

  • ↵† Pennsylvania State College of Medicine, 700 HMC Cres Rd, Hershey, PA 17033

  • ↵# These authors jointly supervised this work

  • Competing interest statement: N.R. and J.B. are co-founders, present/former officers or consultants and/or shareholders of Inivata Ltd, a cancer genomics company that commercialises circulating DNA analysis. C.G.S. has consulted for Inivata Ltd. Inivata had no role in the conception, design, data collection and analysis of the study. Other co-authors have no conflict of interests.

Data Availability

Anonymized data created for the study are or will be available in a persistent repository upon publication.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Refined characterization of circulating tumor DNA through biological feature integration
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Refined characterization of circulating tumor DNA through biological feature integration
Havell Markus, Dineika Chandrananda, Elizabeth Moore, Florent Mouliere, James Morris, James Brenton, Christopher G. Smith, Nitzan Rosenfeld
medRxiv 2021.08.11.21261907; doi: https://doi.org/10.1101/2021.08.11.21261907
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Refined characterization of circulating tumor DNA through biological feature integration
Havell Markus, Dineika Chandrananda, Elizabeth Moore, Florent Mouliere, James Morris, James Brenton, Christopher G. Smith, Nitzan Rosenfeld
medRxiv 2021.08.11.21261907; doi: https://doi.org/10.1101/2021.08.11.21261907

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (217)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1112)
  • Dentistry and Oral Medicine (197)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (508)
  • Epidemiology (9807)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2334)
  • Geriatric Medicine (223)
  • Health Economics (464)
  • Health Informatics (1569)
  • Health Policy (738)
  • Health Systems and Quality Improvement (609)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11674)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2162)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (520)
  • Oncology (1187)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (700)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2196)
  • Public and Global Health (4693)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (459)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (227)
  • Sports Medicine (214)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)